JUMBO TIMI 26

OBJECTIVE: To evaluate the efficacy and safety of prasugrel, a novel thienopyridine, compared to clopidogrel in patients underoing PCI

View/Download
_______________________________________________________________________________

1. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD, Antman EM, Winters KJ, et al. Circulation 2005;111:3366-73.
   | Abstract | Request Reprints |
   
   

2. Clinical correlates and impact of aspirin on the inflammatory response to percutaneous coronary intervention: Results from TIMI 26. Bonaca MP, Morrow DA, Sabatine MS, Murphy SA, Scirica BM, Rifai N, Antman EM, Braunwald E. Circulation 2005;112:II:322.
   | Request Reprints |
   
   
3. Prasugrel suppresses the early rise of sCD40 ligand levels following PCI compared to clopidogrel: A JUMBO-TIMI 26 substudy. Wiviott SD, Morrow DA, Sabatine MS, Murphy SA, Winters KJ, Antman EM, Braunwald E. Circulation 2005;112:II:432.
   | Request Reprints |
   
   
4. Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Bonaca MP, Wiviott SD, Sabatine MS, et al. Am J Cardiol 2007;99:344-8.
   | Abstract | Request Reprints |